Renal Cell Carcinoma Treatment Market: Global Industry Analysis and Forecast (2023-2029)

The Global Renal Cell Carcinoma Treatment Market size was valued at USD 840.82 Million in 2022 and the total Renal Cell Carcinoma Treatment revenue is expected to grow at a CAGR of 6.25% from 2023 to 2029, reaching nearly USD 1285.30 Million.

Overview

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer, accounting for approximately 90% of all kidney cancer cases. It originates in the cells lining the small tubes within the kidney, known as renal tubules. RCC typically grows as a single tumor within one kidney, but it also occurs in both kidneys or spreads to other parts of the body. Several risk factors contribute to the development of RCC, including smoking, obesity, high blood pressure, family history of kidney cancer, certain inherited genetic conditions (such as von Hippel-Lindau disease), and long-term dialysis treatment. Thus, the increasing number of RCC patients driving the need for RCC treatments across the world. Renal cell carcinoma treatment involves surgical options such as nephrectomy, targeted therapies, immunotherapies, and radiation therapy. The increasing incidence of RCC, advancements in treatment options, and ongoing research and development efforts to improve patient outcomes are expected to major factors for driving the renal call treatment market growth during the forecast period. The market is analyzed by the presence of major pharmaceutical companies, research institutions, and healthcare providers working towards developing innovative therapies and personalized treatment approaches. Besides that, the demand for effective treatments, the development of biomarkers for personalized medicine, and the growth of access to innovative therapies are expected to offer lucrative growth opportunities for the renal cell carcinoma treatment market. However, the market is also expected to face challenges, including drug resistance, high treatment costs, and the need for improved biomarker validation.Renal Cell Carcinoma Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

Renal Cell Carcinoma Treatment Market Dynamics:

Increasing Prevalence of Renal Cell Carcinoma The number of renal cell carcinoma patients has been steadily increasing all across the world. One of the more rare types of cancer is malignant alterations in kidney cells. Every year, around 403,000 individuals around the world are diagnosed with kidney cancer, accounting for approximately 2.2% of all new cancer diagnoses. Kidney cancer kills around 175,000 people each year. Renal cell carcinoma (RCC) is the most frequent kind of kidney cancer, accounting for nearly 90% of all diagnoses. Renal cell carcinoma (RCC) accounts for around 4% of all adult malignancies, with roughly 270,000 new cases identified each year globally. In the United States alone, 58,000 new cases of RCC were detected in 2010, with around 13,000 fatalities. In 2021, these figures are expected to rise to 76,080 new cases and 13,780 fatalities. Men are twice as likely as women to be impacted by RCC. The usual age of diagnosis is between 50 and 70 years old.Renal Cell Carcinoma Treatment Market1Factors such as aging populations, changing lifestyles, Smoking, Obesity, High blood pressure (hypertension), etc. contribute to the growing number of RCC cases. Thus, the growing incidence and prevalence of RCC drive the demand for effective stimulate research and development activities, expand the RCC treatment market, and encourage collaborative efforts to address the burden of the disease and contribute to the growth of the renal cell carcinoma treatment market. Pharmaceutical companies and researchers are motivated to develop new therapies and advance existing treatment modalities to address the rising need for RCC treatment. Additionally, efforts to raise awareness about RCC risk factors, promote healthy lifestyles, and improve early detection play an essential role in mitigating the increasing burden of RCC. High Cost of Treatment to Restrain the Market Growth The high cost of renal cell carcinoma (RCC) treatment, particularly targeted therapies, and immunotherapies, is expected to present significant challenges in terms of patient access, healthcare affordability, and reimbursement policies, thereby restraining the real cell carcinoma treatment market growth. Targeted therapies and immunotherapies have revolutionized the treatment landscape for RCC. However, these advanced therapies often come with high price tags. The development and production costs, coupled with the complexity of manufacturing and limited patient populations, contribute to the high cost of these treatments. The high cost of RCC treatment creates barriers to access for many patients, especially those without adequate insurance coverage or financial resources. Patients may face challenges in affording the necessary medications and therapies, potentially leading to delayed or inadequate treatment. This is expected to have a negative impact on patient outcomes and quality of life. In addition, the burden of funding expensive therapies places pressure on healthcare budgets, insurance providers, and government healthcare programs. Balancing the need for innovative and effective treatments with the financial sustainability of healthcare systems is a complex challenge.

Renal Cell Carcinoma Treatment Market Segment Analysis:

Based on treatment types, the Surgical Treatments segment is expected to grow at a significant CAGR during the forecast period. Surgical interventions are commonly adopted in the management of RCC, particularly for localized tumors and certain cases of advanced disease. The treatments are expected to be employed alone or in combination with other treatment modalities, such as targeted therapies or immunotherapies. Combination approaches may involve surgical resection followed by adjuvant therapy or neoadjuvant therapy before surgery. These combination regimens contribute to revenue generation in the renal cell carcinoma treatment market by incorporating surgical procedures alongside other treatment modalities. Surgical treatments are also influenced by factors such as tumor size, stage, location, patient health, and individual treatment goals. Surgical options are often considered when the cancer is localized or when complete or partial removal of the kidney is deemed necessary. Alongside, advancements in surgical techniques have led to the adoption of minimally invasive approaches, such as laparoscopic or robotic-assisted surgeries, for RCC treatment. These techniques offer potential benefits, such as reduced hospital stays, shorter recovery times, and improved cosmetic outcomes. Thus, above mentioned factors are expected to generate the highest revenue in the segment, thereby driving market growth.Renal Cell Carcinoma Treatment Market2The Systemic Therapies (Pharmaceutical Drugs) segment is expected to hold a significant market share by 2029. Systemic therapies are medications that are administered orally or intravenously and work throughout the body to target cancer cells. Tyrosine Kinase Inhibitors (TKIs) such as sunitinib, pazopanib, cabozantinib, and axitinib are commonly used in RCC treatment. They block specific enzymes involved in tumor growth and blood vessel formation. Thus increasing demand for TKIs is expected to boost the segment growth. Immune checkpoint inhibitors, such as nivolumab, pembrolizumab, and avelumab, enhance the immune system's ability to recognize and attack cancer cells. Thus, the rising recommendation of inhibitors by health professionals is further expected to benefit the segment's growth, thereby generating lucrative growth potential for the renal cell carcinoma treatment market. The targeted therapies segment is also expected to positively benefit the renal cell carcinoma treatment industry during the forecast period. Targeted therapies have revolutionized the treatment of RCC by providing more effective and personalized treatment options for patients. They have significantly improved patient outcomes and survival rates, making them a vital component of the RCC market. Continued research and development in this field hold promise for further advancements in targeted therapies and better management of RCC.

Renal Cell Carcinoma Treatment Market Regional Insights:

The North American region is expected to witness a rapid growth rate during the forecast period. The United States, particularly is expected to generate the highest revenue share by 2029. The high incidence rate of kidney cancer in the country is expected to be the major growth factor for the RCC Treatment market. Factors such as lifestyle choices, increased obesity rates, and an aging population contribute to the prevalence of RCC. According to the MMR analysis, In the US, it is estimated that for the year 2020, the number of new cases of kidney cancer is 73,750 and deaths is 14,830, accounting for 2.4% of all cancer-related deaths. In addition, well-developed healthcare infrastructure with advanced diagnostic facilities, specialized treatment centers, and access to innovative therapies, is further expected to support the renal cell carcinoma treatment market growth during the forecast period. North America, particularly the United States, is a hub for research and development in the field of cancer treatment, including RCC. Numerous academic institutions, research organizations, and pharmaceutical companies conduct clinical trials and research studies to explore new treatment modalities and advance existing therapies. These factors further support regional market growth. For instance, • The CLEAR Trial study compared the efficacy of lenvatinib plus pembrolizumab or everolimus versus sunitinib as a first-line treatment for advanced RCC. The trial demonstrated improved progression-free survival and objective response rates in the lenvatinib plus pembrolizumab group. It was conducted from November 2017 to May 2020. • IMmotion151 clinical trial evaluated the combination of atezolizumab and bevacizumab versus sunitinib as a first-line treatment for advanced RCC. The study showed improved progression-free survival in the combination therapy group. It was conducted from March 2016 to September 2017.Renal Cell Carcinoma Treatment Market3Asia Pacific market is expected to generate lucrative growth potentials for the renal cell carcinoma treatment providers during the forecast period. The growing aging population, changing lifestyles, and improved diagnostic capabilities contribute to the rising number of RCC cases, creating a larger patient pool for treatment. Awareness about kidney cancer and RCC has been growing in the Asia-Pacific region. As a result, there is an increased emphasis on early detection and diagnosis, leading to more patients seeking timely medical intervention and treatment, thereby driving the regional market growth. Many countries in the Asia-Pacific region such as China, India, Japan, South Korea, Singapore, Thailand, Vietnam, etc. are investing in healthcare infrastructure development, including advanced medical facilities, specialized cancer treatment centers, and access to innovative therapies. This improved infrastructure enhances the delivery of RCC treatments and expands the market for RCC treatment providers. Besides that, Economies such as China, India, and Southeast Asian countries are experiencing rapid economic growth and healthcare system development. With the increasing disposable income and improving healthcare access, there is a greater ability among patients to afford and access RCC treatments, driving the renal cell carcinoma treatment market growth.

Renal Cell Carcinoma Treatment Market Scope: Inquire before buying

Renal Cell Carcinoma Treatment Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2017 to 2022 Market Size in 2022: US $ 840.82 Mn.
Forecast Period 2023 to 2029 CAGR: 6.25% Market Size in 2029: US $ 1285.30 Mn.
Segments Covered: by Treatment Type 1.Surgical Treatments

3.1. Nephrectomy 3.1.1.Radical nephrectomy 3.1.2.Simple nephrectomy 3.1.3.Partial nephrectomy (selected patients) 3.2.Arterial embolization (palliative) 3.3.Laparoscopic or Robotic-assisted Procedures 3.4.Others

2.Systemic Therapies (Pharmaceutical Drugs)

2.1.Tyrosine Kinase Inhibitors (TKIs) 2.2.mTOR Inhibitors 2.3.Cytokine Therapy 2.4.Immune Checkpoint Inhibitors 2.5.Others

3.Radiation Therapy

3.1.External Beam Radiation 3.2.Brachytherapy

4.Targeted Therapies

4.1.Angiogenesis Inhibitors 4.2.MET Inhibitors

5.Immunotherapies

5.1.Checkpoint Inhibitors 5.2.CAR-T Cell Therapy

6.Supportive Therapies

6.1.Pain Management 6.2.Palliative Care 6.3.Clinical Trials

7.Other Treatment Types
by Treatment Modalities 1.First-line Treatments 2.Second-line Treatments 3.Adjuvant Therapies 4.Others
by End Use 1.Hospitals & Clinic 2.Research Institutes 3.Others

Renal Cell Carcinoma Treatment Market, by Region

North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)

Renal Cell Carcinoma Treatment Providers Key Players:

1.F. Hoffmann-La Roche Ltd. (Switzerland) 2. Mylan N.V. (U.S.) 3. Teva Pharmaceutical Industries Ltd.(Ireland) 4.Sanofi (France) 5.Pfizer Inc. (U.S.) 6.GlaxoSmithKline plc (U.K.) 7.Novartis AG (Switzerland) 8.AstraZeneca (U.K.) 9.Johnson & Johnson Private Limited (U.S.) 10. Cipla (India) 11.Bayer AG (Germany) 12. Eli Lilly and Company (U.S.) 13.Merck & Co., Inc. (U.S.) 14.Allergan (Ireland) 15.Abbott (U.S.) 16. AbbVie Inc. (U.S.) 17.LEO Pharma A/S (Denmark) 18.Bausch Health Companies Inc. (Canada) 19.Sun Pharmaceutical Industries Ltd. (India) 20. Aurobindo Pharma (India) 21.Lupin (India) 22.Hikma Pharmaceuticals PLC (U.K.) 23.Fresenius Kabi AG (Germany) 24.Amneal Pharmaceuticals LLC. (U.S.) 25. Bristol Myers Squibb Company (U.S.) 26.Exelixis, Inc. (U.S.) 27. Eisai Co., Ltd. (Japan) 28. Ipsen Pharma (France) 29.Takeda Pharmaceutical Company Limited (Japan) 30.Amgen Inc. (U.S.) FAQs: 1. What are the growth drivers for the Renal Cell Carcinoma Treatment market? Ans. The increasing prevalence of renal cell carcinoma across the world is expected to be the major driver for the Renal Cell Carcinoma Treatment market. 2. What is the major restraint for the Renal Cell Carcinoma Treatment market growth? Ans: High Costs of treatments are expected to be the major restraining factor for the Renal Cell Carcinoma Treatment market growth. 3. Which region is expected to lead the global Renal Cell Carcinoma Treatment market during the forecast period? Ans. North America is expected to lead the global Renal Cell Carcinoma Treatment market during the forecast period. 4. What is the projected market size & growth rate of the Renal Cell Carcinoma Treatment Market? Ans. The Global Renal Cell Carcinoma Treatment Market size was valued at USD 840.82 Million in 2022 and the total Renal Cell Carcinoma Treatment revenue is expected to grow at a CAGR of 6.25% from 2023 to 2029, reaching nearly USD 1285.30 Million. 5. What segments are covered in the Renal Cell Carcinoma Treatment Market report? Ans. The segments covered in the Renal Cell Carcinoma Treatment market report are Treatment Type, Treatment Modalities, End Use, and Region.
1. Renal Cell Carcinoma Treatment Market: Research Methodology 2. Renal Cell Carcinoma Treatment Market: Executive Summary 3. Renal Cell Carcinoma Treatment Market: Competitive Landscape 3.1. MMR Competition Matrix 3.2. Competitive Landscape 3.3. Key Players Benchmarking 3.4. Market Structure 3.4.1. Market Leaders 3.4.2. Market Followers 3.4.3. Emerging Players 3.5. Consolidation of the Market 4. Renal Cell Carcinoma Treatment Market: Dynamics 4.1. Market Trends by Region 4.1.1. North America 4.1.2. Europe 4.1.3. Asia Pacific 4.1.4. Middle East and Africa 4.1.5. South America 4.2. Market Drivers by Region 4.2.1. North America 4.2.2. Europe 4.2.3. Asia Pacific 4.2.4. Middle East and Africa 4.2.5. South America 4.3. Market Restraints 4.4. Market Opportunities 4.5. Market Challenges 4.6. PORTER’s Five Forces Analysis 4.7. PESTLE Analysis 4.8. Value Chain Analysis 4.9. Regulatory Landscape by Region 4.9.1. North America 4.9.2. Europe 4.9.3. Asia Pacific 4.9.4. Middle East and Africa 4.9.5. South America 4.10. COVID-19 Impact on the Global Renal Cell Carcinoma Treatment Market 5. Renal Cell Carcinoma Treatment Market: Segmentation (by Value USD) 5.1. Renal Cell Carcinoma Treatment Market, by Treatment Type (2022-2029) 5.1.1. Surgical Treatments 5.1.1.1. Nephrectomy 5.1.1.1.1. Radical nephrectomy 5.1.1.1.2. Simple nephrectomy 5.1.1.1.3. Partial nephrectomy (selected patients) 5.1.1.2. Arterial embolization (palliative) 5.1.1.3. Laparoscopic or Robotic-assisted Procedures 5.1.1.4. Others 5.1.2. Systemic Therapies (Pharmaceutical Drugs) 5.1.2.1. Tyrosine Kinase Inhibitors (TKIs) 5.1.2.2. mTOR Inhibitors 5.1.2.3. Cytokine Therapy 5.1.2.4. Immune Checkpoint Inhibitors 5.1.2.5. Others 5.1.3. Radiation Therapy 5.1.3.1. External Beam Radiation 5.1.3.2. Brachytherapy 5.1.4. Targeted Therapies 5.1.4.1. Angiogenesis Inhibitors 5.1.4.2. MET Inhibitors 5.1.5. Immunotherapies 5.1.5.1. Checkpoint Inhibitors 5.1.5.2. CAR-T Cell Therapy 5.1.6. Supportive Therapies 5.1.6.1. Pain Management 5.1.6.2. Palliative Care 5.1.6.3. Clinical Trials 5.1.7. Other Treatment Types 5.2. Renal Cell Carcinoma Treatment Market, by Treatment Modalities (2022-2029) 5.2.1. First-line Treatments 5.2.2. Second-line Treatments 5.2.3. Adjuvant Therapies 5.2.4. Others 5.3. Renal Cell Carcinoma Treatment Market, by End Use (2022-2029) 5.3.1. Hospitals & Clinic 5.3.2. Research Institutes 5.3.3. Others 5.4. Renal Cell Carcinoma Treatment Market, by Region (2022-2029) 5.4.1. North America 5.4.2. Europe 5.4.3. Asia Pacific 5.4.4. Middle East and Africa 5.4.5. South America 6. North America Renal Cell Carcinoma Treatment Market (by Value USD) 6.1. North America Renal Cell Carcinoma Treatment Market, by Treatment Type (2022-2029) 6.1.1. Surgical Treatments 6.1.1.1. Nephrectomy 6.1.1.1.1. Radical nephrectomy 6.1.1.1.2. Simple nephrectomy 6.1.1.1.3. Partial nephrectomy (selected patients) 6.1.1.2. Arterial embolization (palliative) 6.1.1.3. Laparoscopic or Robotic-assisted Procedures 6.1.1.4. Others 6.1.2. Systemic Therapies (Pharmaceutical Drugs) 6.1.2.1. Tyrosine Kinase Inhibitors (TKIs) 6.1.2.2. mTOR Inhibitors 6.1.2.3. Cytokine Therapy 6.1.2.4. Immune Checkpoint Inhibitors 6.1.2.5. Others 6.1.3. Radiation Therapy 6.1.3.1. External Beam Radiation 6.1.3.2. Brachytherapy 6.1.4. Targeted Therapies 6.1.4.1. Angiogenesis Inhibitors 6.1.4.2. MET Inhibitors 6.1.5. Immunotherapies 6.1.5.1. Checkpoint Inhibitors 6.1.5.2. CAR-T Cell Therapy 6.1.6. Supportive Therapies 6.1.6.1. Pain Management 6.1.6.2. Palliative Care 6.1.6.3. Clinical Trials 6.1.7. Other Treatment Types 6.2. North America Renal Cell Carcinoma Treatment Market, by Treatment Modalities (2022-2029) 6.2.1. First-line Treatments 6.2.2. Second-line Treatments 6.2.3. Adjuvant Therapies 6.2.4. Others 6.3. North America Renal Cell Carcinoma Treatment Market, by End Use (2022-2029) 6.3.1. Hospitals & Clinic 6.3.2. Research Institutes 6.3.3. Others 6.4. North America Renal Cell Carcinoma Treatment Market, by Country (2022-2029) 6.4.1. United States 6.4.2. Canada 6.4.3. Mexico 7. Europe Renal Cell Carcinoma Treatment Market (by Value USD) 7.1. Europe Renal Cell Carcinoma Treatment Market, by Treatment Type (2022-2029) 7.2. Europe Renal Cell Carcinoma Treatment Market, by Treatment Modalities (2022-2029) 7.3. Europe Renal Cell Carcinoma Treatment Market, by End Use (2022-2029) 7.4. Europe Renal Cell Carcinoma Treatment Market, by Country (2022-2029) 7.4.1. UK 7.4.2. France 7.4.3. Germany 7.4.4. Italy 7.4.5. Spain 7.4.6. Sweden 7.4.7. Austria 7.4.8. Rest of Europe 8. Asia Pacific Renal Cell Carcinoma Treatment Market (by Value USD) 8.1. Asia Pacific Renal Cell Carcinoma Treatment Market, by Treatment Type (2022-2029) 8.2. Asia Pacific Renal Cell Carcinoma Treatment Market, by Treatment Modalities (2022-2029) 8.3. Asia Pacific Renal Cell Carcinoma Treatment Market, by End Use (2022-2029) 8.4. Asia Pacific Renal Cell Carcinoma Treatment Market, by Country (2022-2029) 8.4.1. China 8.4.2. S Korea 8.4.3. Japan 8.4.4. India 8.4.5. Australia 8.4.6. Indonesia 8.4.7. Malaysia 8.4.8. Vietnam 8.4.9. Taiwan 8.4.10. Bangladesh 8.4.11. Pakistan 8.4.12. Rest of Asia Pacific 9. Middle East and Africa Renal Cell Carcinoma Treatment Market (by Value USD) 9.1. Middle East and Africa Renal Cell Carcinoma Treatment Market, by Treatment Type (2022-2029) 9.2. Middle East and Africa Renal Cell Carcinoma Treatment Market, by Treatment Modalities (2022-2029) 9.3. Middle East and Africa Renal Cell Carcinoma Treatment Market, by End Use (2022-2029) 9.4. Middle East and Africa Renal Cell Carcinoma Treatment Market, by Country (2022-2029) 9.4.1. South Africa 9.4.2. GCC 9.4.3. Egypt 9.4.4. Nigeria 9.4.5. Rest of ME&A 10. South America Renal Cell Carcinoma Treatment Market (by Value USD) 10.1. South America Renal Cell Carcinoma Treatment Market, by Treatment Type (2022-2029) 10.2. South America Renal Cell Carcinoma Treatment Market, by Treatment Modalities (2022-2029) 10.3. South America Renal Cell Carcinoma Treatment Market, by End Use (2022-2029) 10.4. South America Renal Cell Carcinoma Treatment Market, by Country (2022-2029) 10.4.1. Brazil 10.4.2. Argentina 10.4.3. Rest of South America 11. Company Profile: Key players 11.1. F. Hoffmann-La Roche Ltd. (Switzerland) 11.1.1. Company Overview 11.1.2. Financial Overview 11.1.3. Business Portfolio 11.1.4. SWOT Analysis 11.1.5. Business Strategy 11.1.6. Recent Developments 11.2. Mylan N.V. (U.S.) 11.3. Teva Pharmaceutical Industries Ltd.(Ireland) 11.4. Sanofi (France) 11.5. Pfizer Inc. (U.S.) 11.6. GlaxoSmithKline plc (U.K.) 11.7. Novartis AG (Switzerland) 11.8. AstraZeneca (U.K.) 11.9. Johnson & Johnson Private Limited (U.S.) 11.10. Cipla (India) 11.11. Bayer AG (Germany) 11.12. Eli Lilly and Company (U.S.) 11.13. Merck & Co., Inc. (U.S.) 11.14. Allergan (Ireland) 11.15. Abbott (U.S.) 11.16. AbbVie Inc. (U.S.) 11.17. LEO Pharma A/S (Denmark) 11.18. Bausch Health Companies Inc. (Canada) 11.19. Sun Pharmaceutical Industries Ltd. (India) 11.20. Aurobindo Pharma (India) 11.21. Lupin (India) 11.22. Hikma Pharmaceuticals PLC (U.K.) 11.23. Fresenius Kabi AG (Germany) 11.24. Amneal Pharmaceuticals LLC. (U.S.) 11.25. Bristol Myers Squibb Company (U.S.) 11.26. Exelixis, Inc. (U.S.) 11.27. Eisai Co., Ltd. (Japan) 11.28. Ipsen Pharma (France) 11.29. Takeda Pharmaceutical Company Limited (Japan) 11.30. Amgen Inc. (U.S.) 12. Key Findings 13. Industry Recommendation

About This Report

Report ID 189276
Category Healthcare
Published Date May 2023
Updated Date
  • INQUIRE BEFORE BUYING